• Something wrong with this record ?

Nanomedicine of tyrosine kinase inhibitors

V. Smidova, P. Michalek, Z. Goliasova, T. Eckschlager, P. Hodek, V. Adam, Z. Heger

. 2021 ; 11 (4) : 1546-1567. [pub] 20210101

Language English Country Australia

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc21026312

Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026312
003      
CZ-PrNML
005      
20211026133015.0
007      
ta
008      
211013s2021 at f 000 0|eng||
009      
AR
024    7_
$a 10.7150/thno.48662 $2 doi
035    __
$a (PubMed)33408767
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Smidova, Veronika $u Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic
245    10
$a Nanomedicine of tyrosine kinase inhibitors / $c V. Smidova, P. Michalek, Z. Goliasova, T. Eckschlager, P. Hodek, V. Adam, Z. Heger
520    9_
$a Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.
650    12
$a lékové transportní systémy $7 D016503
650    _2
$a lidé $7 D006801
650    12
$a nanomedicína $7 D050997
650    _2
$a nanostruktury $x aplikace a dávkování $x chemie $7 D049329
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $x chemie $x farmakologie $7 D047428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Michalek, Petr $u Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova 656/123, 612 00 Brno, Czech Republic
700    1_
$a Goliasova, Zita $u Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic
700    1_
$a Eckschlager, Tomas $u Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, V Uvalu 84, Prague 5 CZ-15006, Czech Republic
700    1_
$a Hodek, Petr $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic
700    1_
$a Adam, Vojtech $u Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova 656/123, 612 00 Brno, Czech Republic
700    1_
$a Heger, Zbynek $u Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova 656/123, 612 00 Brno, Czech Republic
773    0_
$w MED00177173 $t Theranostics $x 1838-7640 $g Roč. 11, č. 4 (2021), s. 1546-1567
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33408767 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133021 $b ABA008
999    __
$a ok $b bmc $g 1715128 $s 1146819
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 4 $d 1546-1567 $e 20210101 $i 1838-7640 $m Theranostics $n Theranostics $x MED00177173
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options